Tivic CEO to detail NIAID-backed Entolimod GI-ARS preclinical study at April conference
Tivic Health Systems’ CEO Michael Handley will present at the Emerging Growth Virtual Conference on April 1-2 to provide corporate updates. He will discuss the NIAID sponsorship of a preclinical Entolimod study for gastrointestinal acute radiation syndrome, with potential to support future trials upon demonstrated efficacy.
1. Virtual Conference Presentation
Tivic Health Systems CEO Michael Handley will speak at the Emerging Growth Virtual Conference on April 1-2, delivering a corporate update during a 10-minute session scheduled for 2:55-3:05 PM Eastern Time on April 1. The presentation aims to communicate recent milestones and strategic direction to investors and analysts.
2. NIAID Sponsorship for Entolimod GI-ARS
The update will highlight the company's recent agreement with the National Institute of Allergy and Infectious Diseases to sponsor a preclinical study of Entolimod for gastrointestinal acute radiation syndrome. This study under the NIH’s NIAID will evaluate Entolimod’s efficacy in mitigating GI-ARS damage in animal models.
3. Potential for Future Trials
If the preclinical data demonstrate efficacy, NIAID may support subsequent GI-ARS studies using Entolimod, positioning Tivic for further development under the FDA’s Animal Rule. Success in these trials could advance Entolimod toward regulatory milestones and broader therapeutic applications.